El Cytoxan se utiliza para tratar ciertos tipos de los siguientes canceres: linfoma, mieloma múltiple, leucemia, micosis fungoides, neuroblastoma, cáncer de ovario, cáncer ocular y cáncer de mama. Generalmente se utiliza junto con otros medicamentos. También puede utilizarse para tratar ciertos problemas renales (síndrome nefrótico) en niños.
Nuestra página de facturación está certificada por:
U-M researches say common chemotherapy drug enables tumors in bone marrow - AnnArbor.com
U-M researches say common chemotherapy drug enables tumors in bone marrowAnnArbor.
Docs Need Primer on Long-Term Effects of Chemotherapy - Family Practice News Digital Network
Family Practice News Digital NetworkDocs Need Primer on Long-Term Effects of ChemotherapyFamily Practice News Digital NetworkOnly 6% of primary care physicians were able to identify the main long-term effects (LEs) of doxorubicin (Adriamycin), paclitaxel (Taxol), oxaliplatin (Eloxatin), and cyclophosphamide (Cytoxan), compared with 65% of oncologists surveyed.
Some Doctors Unaware of Long-Term Effects of Cancer Care - Cleveland News - Fox 8
Cleveland News - Fox 8Some Doctors Unaware of Long-Term Effects of Cancer CareCleveland News - Fox 8In the case of Cyclophosphamide, only 14% of primary care physicians knew women are likely to suffer premature menopause, compared to 71% of cancer specialists.
Diffuse Large B-Cell Lymphoma: Current Treatment Approaches - Cancer Network
Diffuse Large B-Cell Lymphoma: Current Treatment ApproachesCancer NetworkWhile a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences .
First cycle G-CSF for high-risk chemotherapy: Of Course! - Clinical Oncology News
Clinical Oncology NewsFirst cycle G-CSF for high-risk chemotherapy: Of Course!Clinical Oncology NewsDawn Hershman, MD, of Columbia University in New York City, recently published an article in the Journal of Clinical Oncology noting the rapid uptake of dose-dense AC-Taxol (doxorubicin and cyclophosphamide followed by paclitaxel [ddAC-T]).